Post COVID-19 Disseminated Mucormycosis in a 55-year-old patient in Western Amazon: Case report
Keywords:Mucormycosis, Zygomycosis, Mucormycosis Post COVID-19, Case report
A feared fungal disease surprised and became a warning to severe cases of COVID-19, especially to health professionals involved with the pandemic. Designated as black fungus for public health services in India, where reported data reflects an increase of more than eighty times the expected increase for Rhizopus among the communities. The disease has become even more worrisome due to the high mortality already established as an opportunistic infection, coupled with the reserved prognosis for all those infected and hospitalised by the SARS-CoV-2 severity criteria. This patient, who was submitted to corticosteroid therapy, in an excessive dose, therefore immunosuppressive, developed a severe, disseminated clinical form. It was verified the progression of the lesions and thus the high risk of trans- surgical lethality, or, also, by the insufficiency of conduct in removing the lesions to their satisfaction. Thus, the therapeutic option is the associated use of micafungin, liposomal amphotericin B and isavuconazole for the regressive phase. The patient remains hospitalised with progressive and discrete improvement. Until the opportunity of reevaluation of the surgery by the interspecialty collaboration.
UĞURLU, Ş K. SELIM, S. KOPAR, A. SONGU, M. (2015). Rhino-orbital mucormycosis: Clinical findings and treatment outcomes of four cases. 45. Turkish Journal of Ophthalmology: Galenos Publishing, 2015. Disponível em: https://doi.org/10.4274/tjo.82474. Acesso em: 13 de maio de 2022.
LEWIS, R. Agents of Mucormycosis (Microbiology). Pulmonology Advisor, 2013. Disponível em: https://www.pulmonologyadvisor.com/home/decis ion-support-in-medicine/infectious- diseases/agents-of-mucormycosis-microbiology/. Acesso em: 13 de maio de 2022.
ABIDI, M Z. SOHAIL, M R. et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: A comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. 57. Mycoses: Wiley, 2014. Disponível em: https://doi.org/10.1111/myc.12222. Acesso em: 13 de maio de 2022.
NISHIOKA, S A. Mucormicose e COVID-19 na Índia. UNASUS, 2021. Disponível em: https://www.unasus.gov.br/especial/covid19/mark down/411#:~:text=J%C3%A1%20antes%20da%2 0pandemia%20a,0%2C06%20casos%20por%20
000. Acesso em: 13 de maio de 2022. Mucormicose (Fungo Negro). Ministério da Saúde, 2021. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude- de-a-a-z/m/mucormicose-fungo-negro-1. Acesso em:13 de maio de 2022.
FUCHS, A. PORTUGAL, J. GONÇALVES, P. Fiocruz é referência nacional para o diagnóstico da mucormicose. Fiocruz, 2021. Disponível em: https://portal.fiocruz.br/noticia/fiocruz-e-referencia- nacional-para-o-diagnostico-da-mucormicose. Acesso em: 13 de maio de 2022.
Doenças infecciosas Agentes de Mucormicose (Microbiologia), 2022. https://www.google.com/url?sa=t&source=web&rc t=j&url=https://www.saude.go.gov.br/files//conecta-sus/produtos-tecnicos/I%2520I-%25202021/COVID-19%2520-%2520Fungo%2520negro%2520(mucormicose).p df&ved=2ahUKEwji3NKyupH4AhUiRLgEHXvyCm sQFnoECBIQAQ&usg=AOvVaw3LWAh8Cgy20R viur8Ao93y. Acesso em: 13 de maio de 2022.
GARY, M C. Mucormicose (zigomicose). UpToDate, 2022. Acesso em: 13 de maio de 2022.
Copyright (c) 2022 Neves SAVM, SilvaLLS, Patzina RA, Ponce CC, Cordeiro JS, Araújo AO, Lima EL, Matos IS, Furtado JJD, Pussi LV, Cavalcante EA, Silva MV
This work is licensed under a Creative Commons Attribution 4.0 International License.